SPL028

SPL028, or SPL-028, also known as α,α-dideutero-N,''N-dimethyltryptamine, is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders. It is the analogue of dimethyltryptamine in which the α carbon has been dideuterated. SPL028's route of administration is intravenous injection or intramuscular injection.
The drug shows similar pharmacodynamics as DMT in vitro''. Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests. On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration. In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.
SPL028 was originated by Small Pharma and is under development by Cybin. Small Pharma was acquired by Cybin in 2023. As of February 2024, SPL028 is in phase 1 clinical trials.